DUBLIN, March 25, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/llq9cw/investigation) has announced the addition of the "Investigation Report on China Bevacizumab Market, 2009-2018" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Bevacizumab is an important kind of remedy for metastatic colon cancer, which belongs to humanized anti-VEGF monoclonal antibody. Approved by FDA, bevacizumab came into the market in 2004, with the brand name of ""Avastin"". Its main mechanism is to inhibit the function of a natural protein called vascular endothelial growth factor (VEGF) that stimulates new blood vessel formation through specific binding so as to stop or delay growth of blood vessels in tumor, disconnect the delivery of oxygen and other nutrition necessary in tumor cells' growth, as well as to improve the effect of chemotherapy remedy. Public data shows that the global sales value of bevacizumab in 2012 exceeded USD 6.3 billion, ranking the fourth among the 10 best selling monoclonal antibody drugs.
As Chinese economy develops rapidly, Chinese people's lifestyle is changing tremendously. With the aging level increasing, environment pollution worsening, the incidence of cancer in China keeps rising. Statistics indicate that the annual increase of cancer patients in China takes up over 20% of the global, making China a capital antitumor remedy market of the world. Shanghai Roche Pharmaceuticals Ltd. declared on May 7, 2010 that its bevacizumab injection (brand name ""Avastin"") was approved by the FDA for curing metastatic colorectal cancer. It is the official entry of the world's first angiogenesis inhibitor into Chinese market. The market investigation of CRI manifests that the sales value of Avastin in certain Chinese sample hospitals in 2010 was merely CNY 10 million, growing rapidly. It broke through CNY 200 million in 2013.
There have been some generic drug manufacturers developing bevacizumab around the world. At the end of 2013, Huahai Pharmaceutical in China announced that its bevacizumab generic drug developed with Oncobiologics Company was approved to conduct the first clinical trial in the European Union.
Some study declared that the combination of bevacizumab and chemotherapy can prolong overall survival time of advanced cervical cancer patients. This result indicates the possibility of this remedy with the annual sales value of USD 1 billion to treat cervical cancer.
Key Topics Covered:
1 Relevant Concepts of Bevacizumab
2 Market Overview of Bevacizumab in China, 2010-2013
3 Investigation on Sales Value of Bevacizumab in China, 2010-2013
4 Investigation on Market Share of Major Bevacizumab Manufacturers in China, 2010-2013
5 Investigation on Market Size of Bevacizumab by Dosage Form in China, 2010-2013
6 Reference Price of Bevacizumab in Hospital Market in China, 2010-2013
7 Prospect of China Bevacizumab Market, 2014-2018
- Shanghai Roche Pharmaceuticals Ltd.
For more information visit http://www.researchandmarkets.com/research/llq9cw/investigation
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets